Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$520,000 |
 |
Gilead SciencesGILD |
-$2B |
 |
Anavex Life SciencesAVXL |
-$6.3M |
 |
AmgenAMGN |
-$109M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Harper Molly | Dec 12, 2025 | Sell | 15,527 | $23.198 | $360,000 |
| Harper Molly | Dec 12, 2025 | Sell | 6,746 | $23.06 | $160,000 |
| Harper Molly | Dec 12, 2025 | Sell | 4,473 | $23.734 | $110,000 |
| Del Carmen Jeffrey | Nov 26, 2025 | Sell | 10,983 | $23.331 | $260,000 |
| Elsbernd Brian | Nov 12, 2025 | Sell | 40,000 | $22.7 | $910,000 |
| Elsbernd Brian | Sep 8, 2025 | Sell | 30,000 | $20.3 | $610,000 |
| Elsbernd Brian | Sep 4, 2025 | Sell | 30,000 | $19.52 | $590,000 |
| Elsbernd Brian | Sep 3, 2025 | Sell | 20,000 | $20.08 | $400,000 |
| Tierney David S | Aug 27, 2025 | Sell | 26,000 | $20.2 | $530,000 |
| Miller Steve | Aug 26, 2025 | Sell | 115,000 | $20.28 | $2.3M |
| Daly Richard J | Aug 26, 2025 | Sell | 22,970 | $20.62 | $470,000 |
| Sundaram Preethi | Jun 11, 2025 | Sell | 1,600 | $26.42 | $42,000 |
| Sundaram Preethi | Jun 10, 2025 | Sell | 2,324 | $26.41 | $61,000 |
| MCENANY PATRICK J | Jun 9, 2025 | Sell | 171,748 | $26.11 | $4.5M |
| MCENANY PATRICK J | Jun 6, 2025 | Sell | 28,252 | $25.945 | $730,000 |
| Daly Richard J | May 30, 2025 | Sell | 70,000 | $24.86 | $1.7M |
| INGENITO GARY | May 14, 2025 | Sell | 44,000 | $23.63 | $1M |
| INGENITO GARY | May 13, 2025 | Sell | 200,000 | $23.68 | $4.7M |
| INGENITO GARY | Mar 6, 2025 | Sell | 180,096 | $21.67 | $3.9M |
| INGENITO GARY | Mar 5, 2025 | Sell | 44,904 | $22.09 | $990,000 |
| Elsbernd Brian | Mar 3, 2025 | Sell | 53,255 | $22.93 | $1.2M |
| Del Carmen Jeffrey | Mar 3, 2025 | Sell | 30,423 | $22.89 | $700,000 |
| Elsbernd Brian | Mar 3, 2025 | Sell | 9,720 | $23.23 | $230,000 |
| Miller Steve | Dec 10, 2024 | Sell | 50,000 | $21.927 | $1.1M |
| Harper Molly | Nov 27, 2024 | Sell | 17,500 | $22 | $390,000 |
| INGENITO GARY | Nov 27, 2024 | Sell | 8,631 | $22.74 | $200,000 |
| INGENITO GARY | Nov 27, 2024 | Sell | 3,369 | $22.673 | $76,000 |
| Elsbernd Brian | Nov 26, 2024 | Sell | 9,300 | $21.65 | $200,000 |
| Elsbernd Brian | Nov 26, 2024 | Sell | 3,956 | $21.577 | $85,000 |
| INGENITO GARY | Nov 20, 2024 | Sell | 38,000 | $21.199 | $810,000 |
| MCENANY PATRICK J | Nov 20, 2024 | Sell | 72,500 | $21.29 | $1.5M |
| MCENANY PATRICK J | Nov 19, 2024 | Sell | 98,345 | $21.188 | $2.1M |
| MCENANY PATRICK J | Nov 14, 2024 | Sell | 44,655 | $21.752 | $970,000 |
| MCENANY PATRICK J | Nov 13, 2024 | Sell | 92,500 | $22.978 | $2.1M |
| MCENANY PATRICK J | Nov 12, 2024 | Sell | 192,000 | $23.201 | $4.5M |
| MCENANY PATRICK J | Nov 12, 2024 | Sell | 70,000 | $23.421 | $1.6M |
| MCENANY PATRICK J | Nov 11, 2024 | Sell | 230,000 | $23.548 | $5.4M |
| Tierney David S | Aug 21, 2024 | Sell | 15,000 | $20.097 | $300,000 |
| Miller Steve | Aug 20, 2024 | Sell | 50,000 | $20.585 | $1M |
| INGENITO GARY | Aug 9, 2024 | Sell | 100,000 | $18.04 | $1.8M |
| Del Carmen Jeffrey | Aug 9, 2024 | Sell | 30,000 | $18.42 | $550,000 |
| Del Carmen Jeffrey | Aug 9, 2024 | Sell | 6,058 | $18.44 | $110,000 |
| Del Carmen Jeffrey | Jun 7, 2024 | Sell | 7,541 | $16.07 | $120,000 |
| INGENITO GARY | Jun 5, 2024 | Sell | 80,000 | $16.16 | $1.3M |
| Daly Richard J | Jun 4, 2024 | Sell | 17,323 | $15.975 | $280,000 |
| Harper Molly | Jun 3, 2024 | Sell | 5,333 | $16.304 | $87,000 |
| Tierney David S | Apr 8, 2024 | Sell | 25,000 | $15.68 | $390,000 |
| Elsbernd Brian | Mar 27, 2024 | Sell | 25,000 | $16.44 | $410,000 |
FAQ - Insider Transactions
The most recent insider transaction for Catalyst Pharmaceuticals was conducted by Harper Molly, who sold 15,527 shares on December 12, 2025 at a price of $23.20 per share.
MCENANY PATRICK J has sold the most CPRX stock in the last 2 years, with a total value of $23M.
The total value of insider transactions for Catalyst Pharmaceuticals in the last 2 years is negative, amounting to -$54M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Catalyst Pharmaceuticals have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
